ap

APO-ESCITALOPRAM escitalopram (as oxalate) 20 mg tablet blister (escitalopram oxalate)

Manufacturing




ap

TACROGRAF tacrolimus 1 mg capsule bottle (tacrolimus monohydrate)

Manufacturing




ap

APO-BISOPROLOL bisoprolol fumarate 2.5mg tablet blister pack (bisoprolol fumarate)

Manufacturing




ap

APO-CITALOPRAM citalopram 40 mg (as hydrobromide) tablet blister pack (citalopram hydrobromide)

Manufacturing




ap

APO-OLANZAPINE ODT olanzapine 20 mg orally disintegrating tablet blister pack (olanzapine)

Manufacturing




ap

APO-NEBIVOLOL nebivolol (as hydrochloride) 5 mg tablet blister pack (nebivolol hydrochloride)

Manufacturing




ap

TACIDINE nizatidine 300mg capsule blister pack (nizatidine)

Unexpected increase in demand due to other sponsors unable to supply




ap

APO-SIMVASTATIN simvastatin 20 mg tablet blister pack (simvastatin)

Manufacturing




ap

NUPENTIN 300 gabapentin 300 mg capsule blister pack (gabapentin)

Manufacturing




ap

DUODART 500/400 dutasteride 500 microgram and tamsulosin hydrochloride 400 microgram modified release capsule bottle (tamsulosin hydrochloride)

Manufacturing




ap

DUODART 500/400 dutasteride 500 microgram and tamsulosin hydrochloride 400 microgram modified release capsule bottle (dutasteride)

Manufacturing




ap

PFIZER DAPTOMYCIN daptomycin 350 mg powder for injection vial (daptomycin)

Manufacturing




ap

APO-TOPIRAMATE topiramate 100 mg tablet blister pack (topiramate)

Manufacturing




ap

MOXICAM meloxicam 15 mg capsule blister pack (meloxicam)

Manufacturing




ap

APX-AMOXICILLIN/CLAVULANIC ACID 500/125 amoxicillin 500 mg (as trihydrate) & clavulanic acid 125 mg (as potassium) tablet strip pack (potassium clavulanate)

Commercial Changes / Commercial viability




ap

APX-AMOXICILLIN/CLAVULANIC ACID 500/125 amoxicillin 500 mg (as trihydrate) & clavulanic acid 125 mg (as potassium) tablet strip pack (amoxicillin trihydrate)

Commercial Changes / Commercial viability




ap

FLUZOLE 200 fluconazole 200mg capsule blister pack (fluconazole)

Commercial Changes / Commercial viability




ap

APO-TRAMADOL SR tramadol hydrochloride 200 mg oral tablet blister pack (tramadol hydrochloride)

Manufacturing




ap

APO-ZOLMITRIPTAN zolmitriptan 2.5mg tablet blister pack (zolmitriptan)

Manufacturing




ap

APO-ATOMOXETINE atomoxetine (as hydrochloride) 100 mg capsule blister (atomoxetine hydrochloride)

Manufacturing




ap

APO-LEVETIRACETAM levetiracetam 1000 mg film coated tablet blister pack (levetiracetam)

Manufacturing




ap

GAMINE XR galantamine (as hydrobromide) 16mg modified release capsules blister pack (galantamine hydrobromide)

Manufacturing




ap

CERVARIX human papillomavirus vaccine types 16 and 18 [recombinant, AS04 adjuvanted] suspension for injection pre-filled syringe (HPV Type 18 L1 Protein)

Commercial Changes / Commercial viability




ap

CERVARIX human papillomavirus vaccine types 16 and 18 [recombinant, AS04 adjuvanted] suspension for injection pre-filled syringe (HPV Type 16 L1 Protein)

Commercial Changes / Commercial viability




ap

Regulation (EU) 2024/1938 of the European Parliament and of the Council of 13 June 2024 on Standards of Quality and Safety for Substances of Human Origin Intended for Human Application and Repealing Directives 2002/98/EC and 2004/23/EC

Room 21, Parliament Buildings



  • Windsor Framework Democratic Scrutiny Committee

ap

Regulation (EU) 2024/1938 on Standards of Quality and Safety for Substances of Human Origin intended for Human Application

Room 21, Parliament Buildings



  • Windsor Framework Democratic Scrutiny Committee

ap

Inquiry into Gaps in Equality Legislation: Equality Coalition

Room 30, Parliament Buildings



  • Committee for The Executive Office

ap

Inquiry into Gaps in Equality Legislation: Equality Commission for Northern Ireland

Room 30, Parliament Buildings



  • Committee for The Executive Office

ap

Inquiry into Gaps in Equality Legislation: Age NI; Commissioner for Older People for Northern Ireland

Room 30, Parliament Buildings



  • Committee for The Executive Office

ap

‘Major Capital Projects: Follow-up Report’: Executive Office; Department of Finance; Strategic Investment Board; Northern Ireland Audit Office

Room 30, Parliament Buildings



  • Public Accounts Committee

ap

Financial Landscape in the United Kingdom and Ireland: Financial Services Union

Room 21, Parliament Buildings



  • Committee for Finance

ap

Impact of Northern Ireland Water’s Capacity Constraints on the Construction Sector: Construction Employers Federation; Royal Society of Ulster Architects

Room 29, Parliament Buildings



  • Committee for Infrastructure

ap

Plenary, 08 April 2024

Assembly Chamber, Parliament Buildings




ap

Plenary, 09 April 2024

Assembly Chamber, Parliament Buildings




ap

Plenary, 15 April 2024

Assembly Chamber, Parliament Buildings




ap

Plenary, 16 April 2024

Assembly Chamber, Parliament Buildings




ap

Plenary, 22 April 2024

Assembly Chamber, Parliament Buildings




ap

Plenary, 23 April 2024

Assembly Chamber, Parliament Buildings




ap

Plenary, 29 April 2024

Assembly Chamber, Parliament Buildings




ap

Plenary, 30 April 2024

Assembly Chamber, Parliament Buildings




ap

Stanford Medicine experts help Nobel winner custom design proteins for COVID-19 therapy

Custom designing proteins — a breakthrough recognized by the latest Nobel Prize in chemistry — could yield treatments that stop the worst of COVID-19 before it begins.

The post Stanford Medicine experts help Nobel winner custom design proteins for COVID-19 therapy appeared first on Scope.




ap

Committee disappointed with Translink fare hikes

The Committee for Infrastructure has expressed its disappointment at a Translink fare hike at their last meeting before the election.




ap

Backlog of blue badge applications still a problem

The Northern Ireland Assembly Committee for Infrastructure has criticised the Department’s handling of the backlog in issuing blue badges to those with mobility issues at their meeting today.




ap

Committee welcomes online blue badges applications

The Northern Ireland Assembly Committee for Infrastructure has welcomed the introduction of online applications for blue badges.




ap

Debra Lilley on Fusion Applications (Part 1 of 3)

Oracle ACE Director Debra Lilley of Fujitsu talks about her role as the Director and Deputy Chairperson of the UK Oracle User Group (UKOUG) and about the UKOUG development group's involvement in Oracle Fusion Applications.




ap

Debra Lilley on Fusion Applications (Part 2 of 3)

Oracle ACE Director Debra Lilley of Fujitsu talks about Fusion Applications and their implications for Enterprise Architecture, and the importance of user experience.




ap

Debra Lilley on Fusion Applications (Part 3 of 3)

Oracle ACE Director Debra Lilley of Fujitsu talks about closing the gap between IT and business, and about how business users should be able to use applications without having to think about the underlying technology.




ap

Unwrapping Oracle WebLogic Server 12c - Part 1

A conversation with the Oracle Weblogic Server product management team about community involvement in WebLogic's evolution.




ap

Unwrapping Oracle WebLogic Server 12c - Part 2

A discussion of the relationship between Oracle Weblogic 12c and Oracle Virtual Assembly Builder.




ap

Unwrapping Oracle WebLogic Server 12c - Part 3

A conversation about Oracle WebLogic 12c's role in the evolution of Oracle Fusion Middleware, plus a quick overview of product information resources.